Tuesday 17 November 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
3.11
0.33
−9.59%
Follow KYNB
Alert me
Where the cash went Twelve months to 30 June 2026
Free cash flow was −$38.1M: capital expenditures were more than operating cash flow. Cash fell by $69.2M. Lines the picture does not name came to −$87.3M. What is a cash flow statement?
- Free cash flow
- −$38.1M
- Returned to shareholders
- $0.00
- Debt, net
- $0.00 borrowed
- Change in cash
- −$69.2M over the period
| Operating cash flow | 0.0 |
|---|---|
| Free cash flow | 0.0 |
| Acquisitions, net | +0.1 |
| Into investments, net | 0.0 |
| Other | −0.1 |
| Change in cash | −0.1 |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more TTM periods Free account |
215.65 | 183.45 | 163.62 | 183.19 |
Depreciation & Amortization |
1.09 | 0.68 | 0.17 | (0.14) | |
Non Cash Items (Other) |
(37.69) | (35.87) | (38.06) | (70.29) | |
Accounts Receivable Change |
6.77 | (2.54) | (4.21) | 0.33 | |
Change in inventories |
9.75 | 5.36 | 2.86 | 1.51 | |
Accounts Payable Change |
(3.09) | (27.65) | (1.54) | (2.20) | |
Change in payables and accrued liability |
(117.02) | (45.51) | (16.93) | (11.05) | |
Change in other assets and liabilities |
(92.37) | (82.69) | (127.30) | (139.40) | |
Operating Cash Flow |
(16.91) | (4.77) | (21.38) | (38.05) | |
Capital expenditures |
0.03 | (0.04) | — | — | |
Net Aquisitions |
91.42 | 96.59 | 96.53 | 100.55 | |
Short Term Investments Change (Net) |
(3.03) | (61.16) | (72.21) | (76.16) | |
Long-Term Investments Change (Net) |
— | — | 88.04 | 33.42 | |
Other investing activities |
— | — | — | 48.34 | |
Investing cash flow |
88.85 | 35.42 | 38.45 | 56.14 | |
Repayment/Issuance of Debt (Net) |
(80.56) | (80.56) | — | — | |
Other financial activities |
(5.47) | (5.47) | (5.39) | (5.38) | |
Financing cash flow |
(86.01) | (86.03) | (85.95) | (85.94) | |
Exchange Rate Adjustment |
1.04 | 1.08 | (0.33) | (1.34) | |
Change in Cash |
(13.03) | (54.31) | (69.20) | (69.20) | |
Beginning Cash |
102.18 | 102.18 | 47.87 | 47.87 | |
Ending Cash |
89.15 | 47.87 | (21.33) | (21.32) | |
Stock Based Compensation |
5.57 | 6.58 | 4.88 | 3.99 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(195.97) | (153.03) | (147.11) | (150.82) | |
Investments Change (Net) |
70.87 | (59.50) | (56.42) | (44.40) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026